GKOS— AI Stock Forecast & Price Targets
Published 8/13/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live GKOS price forecast →
GKOS shows strong technical momentum driven by recent earnings beat and guidance raise, but faces significant valuation challenges with negative margins and high debt. The stock is trading near 52-week highs with aggressive short interest, while analyst targets suggest upside potential above current price. Key catalysts include clinical progress on GLK-321 and market adoption of iStent inject stents.
Hold near $184 support; if price breaks above $186.75 with volume, consider adding to position. Invalidation at $182 (recent swing low).
Target $193.62 based on analyst consensus and Kronos AI forecast. Catalysts include GLK-321 Phase 2 results and continued market adoption of iStent inject stents. Change of mind if margins turn positive or debt reduction occurs.
Terminal value driven by successful commercialization of iDose TR and Epioxa, with potential for $200+ valuation if clinical milestones are met. Structural risk is regulatory delays impacting product approvals.
Revenue growth is robust at 41.5% YoY, driven by strong adoption of iDose TR and iStent inject stents. However, negative operating margins (-12.89%) and profit margins (-30.68%) indicate severe financial headwinds. The balance sheet shows high debt-to-equity (15.77) but positive free cash flow generation ($12.09M in Q2 2026). Institutional ownership is strong at 101.46%, but insider selling signals caution.
The chart shows a sharp uptrend with price breaking above $185 (52-week high) and trading near $186.63. The forecast band from Kronos AI suggests upside potential to $193.62, but the RSI of 83.07 indicates overbought conditions. Support is at $184 (recent swing low), with resistance at $186.75 (52-week high). The model's directional accuracy for short-term forecasts is poor (15% vs naive baseline), suggesting momentum may be unsustainable.
Recent news highlights record Q2 sales ($185.6M) and raised guidance to $680-700M, with analysts raising price targets up to $195 (HC Wainwright). Negative margins (-30.68%) and high debt (D/E 15.77) remain concerns. Insider selling by CFO Thurman Alex R. ($3.6M on Aug 7) signals internal caution despite strong technical momentum.
- GLK-321 Phase 2 results expected to confirm efficacy for Demodex Blepharitis (near-term catalyst)
- iStent inject micro-bypass stents gaining market share with 41.5% YoY sales growth
- Sustained negative margins (-30.68%) despite revenue growth
- High debt load (D/E 15.77) relative to cash flow generation
- Regulatory delays impacting key product approvals
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord